BIO:ON Insight #11 · Aug 4, 2026
Rejected three times, fighting for ten years — so why did all three win this week?
J&J offers $5.5B to settle 76,000 talc lawsuits, GSK pays $110M for AI biotech Relation's biological data, and twice-rejected cancer virus RP1 wins an FDA advisory vote. Can you put a price on failure?
What I learned this week
If I had to sum up this week in one line: "resolved" usually just means you've got a ticket to the next round. Still, I found this week's news encouraging. Like Replimune knocking on the door a third time after two rejections, failure in this industry isn't always the end; sometimes it becomes data. See you next issue. 🙏
Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.
Stories in this issue
- Market Trends
J&J offers $5.5B to settle 76,000 talc lawsuits
Johnson & Johnson
- Pipeline Analysis
GSK × Relation: $110M AI target discovery partnership
GSKRelation Therapeutics
- FDA Approvals
Replimune's RP1 wins an FDA advisory vote after two CRLs
ReplimuneRP1US FDA
AI summary
- 1J&J proposed a $5.5B settlement covering 76,000 talc powder lawsuits.
- 2GSK's $110M deal with AI biotech Relation signals drug discovery shifting from compute to data.
- 3Twice-rejected oncolytic virus RP1 won a favorable FDA advisory committee vote.
Relevant rolesRegulatory affairsBDInvestment & IR
Summary and tags generated by AI from the issue text.
References
- 1.J&J offers $5.5B to settle 76,000 talc lawsuits (opens in a new tab)
Fierce Pharma, Jul 28, 2026
- 2.GSK × Relation Therapeutics — $110M AI target discovery partnership (opens in a new tab)
Fierce Biotech, Jul 30, 2026
- 3.Replimune's twice-rejected RP1 wins FDA advisory committee vote (opens in a new tab)
Fierce Biotech, Jul 30, 2026
Related insights
Other issues covering the same companies, drugs or topics